Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 7/20 | 0.43 |
| ▸ | KIT | P10721 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 10/20 | 0.41 |
| ▸ | AURKA | O14965 | 4/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | SIK1 | P57059 | 1/20 | 0.37 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.37 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28912477 | 1.00 | SRC (0.44) | SRCGSTO1FLT3KITKDR | |
| SCHEMBL29911550 | 0.93 | KIT (0.45) | SRCFLT3KITCHEK1LCK | |
| SCHEMBL22917630 | 0.93 | KIT (0.45) | SRCFLT3KITCHEK1LCK | |
| SCHEMBL28912478 | 0.93 | KIT (0.45) | SRCFLT3KITCHEK1LCK | |
| SCHEMBL28912515 | 0.89 | SRC (0.42) | SRCFLT3KITKDRAURKA | |
| SCHEMBL22917499 | 0.89 | SRC (0.42) | SRCFLT3KITKDRAURKA | |
| SCHEMBL22917565 | 0.89 | SRC (0.44) | SRCGSTO1FLT3KITKDR | |
| SCHEMBL22917462 | 0.89 | FLT3 (0.46) | SRCFLT3KITKDRAURKA | |
| SCHEMBL28912456 | 0.89 | FLT3 (0.46) | SRCFLT3KITKDRAURKA | |
| SCHEMBL22917581 | 0.88 | FLT3 (0.44) | SRCGSTO1FLT3KITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288069-A1 | INHIBITORS OF TYROSINE KINASE | BRIDGENE BIOSCIENCES, INC. | 2022-09-15 | — | — | US | disclosed |
| EP-3999064-A1 | INHIBITORS OF TYROSINE KINASE | Bridgene Biosciences, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114401722-A | Inhibitors of tyrosine kinases | 布里奇恩生物科学公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2021016102-A1 | INHIBITORS OF TYROSINE KINASE | BRIDGENE BIOSCIENCES, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288069-A1 | INHIBITORS OF TYROSINE KINASE | ABL1, SRC, LCK | SRC 2/4885GSTO1 1550/4885FLT3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.